trending Market Intelligence /marketintelligence/en/news-insights/trending/RPHs1fjr8U_plLBHwW8LmQ2 content esgSubNav
In This List

Bristol-Myers extends date of debt exchange offers related to Celgene merger

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Bristol-Myers extends date of debt exchange offers related to Celgene merger

Bristol-Myers Squibb Co. has extended the expiration date of offers to exchange notes issued by Celgene Corp. for up to $19.85 billion of new notes and cash.

The New York-based pharmaceutical giant started the exchange offers in connection with its acquisition of Celgene for $95 billion.

The offers will now expire July 8 instead of June 3. Bristol-Myers said the expiration date of the exchange offers may be further extended and the company will give notice of any such extension.

The exchange offer is subject to certain conditions including the closing of the Celgene transaction, which is expected in the third quarter.